Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.
This study compared immune responses of healthy Aboriginal and non-Aboriginal infants to Haemophilus influenzae type b (Hib) and hepatitis B virus (HBV) components of a DTaP-HBV-IPV/Hib combination vaccine, 1 month after completing dosing at 2, 4 and 6 months of age. Of 112 infants enrolled in each group, 94 Aboriginal and 107 non-Aboriginal infants qualified for the immunogenicity analysis. Anti-PRP concentrations exceeded the protective minimum (≥0.15 μg/ml) in ≥97% of infants in both groups but geometric mean concentrations (GMCs) were higher in Aboriginal infants (6.12 μg/ml versus 3.51 μg/ml). All subjects were seroprotected (anti-HBs ≥10 mIU/mL) against HBV, with groups having similar GMCs (1797.9 versus 1544.4 mIU/mL, Aboriginal versus non-Aboriginal, respectively). No safety concerns were identified. We conclude that 3-dose primary vaccination with DTaP-HBV-IPV/Hib combination vaccine elicited immune responses to Hib and HBV components that were at least as high in Aboriginal as in non-Aboriginal Canadian infants. Clinical Trial Registration NCT00753649.
['Scheifele|David W|DW|', 'Ferguson|Murdo|M|', 'Predy|Gerald|G|', 'Dawar|Meena|M|', 'Assudani|Deepak|D|', 'Kuriyakose|Sherine|S|', 'Van Der Meeren|Olivier|O|', 'Han|Htay-Htay|HH|']
D000907:Antibodies, Bacterial D002170:Canada D003140:Communicable Disease Control D015721:Diphtheria-Tetanus-Pertussis Vaccine D005260:Female D018073:Haemophilus Vaccines D006510:Hepatitis B Antibodies D017325:Hepatitis B Vaccines D006801:Humans D007223:Infant D008297:Male D062486:Public Health Surveillance D014611:Vaccination
Immunogenicity Safety Aboriginal Hepatitis B Combination vaccine Haemophilus influenzae b